Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking...

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Nuclear factor-kappa B (NF-κB) signaling is crucial in oncogenesis and immunity, presenting a therapeutic target.
• Selective inhibition of NF-κB for antitumor activity remains a challenge.

Purpose of the Study:

• To investigate the therapeutic potential of IT-901, a novel naphthalenethiobarbiturate derivative.
• To elucidate the mechanism of action of IT-901 in treating B-cell lymphoma and graft-versus-host disease.

Main Methods:

• Preclinical assessment of IT-901 in vitro and in vivo models of human B-cell lymphoma.
• Evaluation of IT-901's effects on NF-κB signaling, redox homeostasis, and oxidative stress.
• Assessment of IT-901's impact on graft-versus-host disease and graft-versus-lymphoma activity.

Main Results:

• IT-901 potently inhibits the NF-κB subunit c-Rel.
• IT-901 demonstrated antitumor properties against B-cell lymphoma, independent of NF-κB dependency.
• The drug modulated redox homeostasis, inducing oxidative stress selectively in lymphoma cells.
• IT-901 suppressed graft-versus-host disease while preserving graft-versus-lymphoma activity.
• IT-901 did not increase reactive oxygen species in normal leukocytes, indicating cancer selectivity.

Conclusions:

• IT-901 exhibits preclinical efficacy as a novel therapeutic agent for human lymphoid tumors.
• IT-901's mechanism involves inducing oxidative stress and inhibiting NF-κB signaling.
• IT-901 shows potential for ameliorating graft-versus-host disease and treating lymphoma.